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A b s t r a c t  
Fast dissolving drug delivery systems have gained patient acceptability and popularity in the recent 
times. The purpose of this work was to develop mouth dissolving oral films of Palonosetron HCl is an 
antiemetic drug especially used in the prevention and treatment of chemotherapy-induced nausea and 
vomiting . An attempt was made to prepare oral dissolving films by solvent casting method. The films 
were prepared by using different grades of HPMC E3, E6 and E15, maltodextrin DE6 and other 
polymers by solvent casting method. They were evaluated for physical characteristics such as 
thickness, uniformity of weight, folding endurance, drug content, surface pH, percentage elongation 
and tensile strength and results were found to be satisfactory. The formulations were subjected to 
disintegration and in-vitro drug release test.  
The in vitro disintegration time of the optimized formulation F13 was10sec and drug release was found 
to be very fast i.e. 99.52% of within 10 min when compared with innovator product i.e 80.5%. In 
vivo studies confirmed that their potential as an innovative dosage form to improve the bioavailability 
and considered to be potentially useful for the treatment of emesis where quick onset of action is 
desirable. DSC and FTIR data revealed that no interactions takes place between the drug and 
polymers used in the optimized formulation. From the above results, it can be a good alternative to 
conventional Palonosetron tablets in the treatment of emesis. In vitro and in vivo evaluation of the films 
confirmed their potential as an innovative dosage form to improve delivery and quick onset of action 
of Granisetron Hydrochloride. Therefore, the oral fast dissolving film is considered to be potentially 
useful for the treatment of emesis disease where quick onset of action is desired, also improved patient 
compliance. 
Keywords: Palonosetron, emesis, mouth dissolving oral films, disintegration time, HPMC, 
Pharmacokinetics. 
 
Introduction 
Mouth dissolving films offers an elegant route for systemic drug 
delivery. The improved systemic bioavailability results from 
bypassing first pass effect and permeability due to a well supplied 
vascular and lymphatic drainage.Also, large surface area of 
absorption, easy ingestion and swallowing, pain avoidance make the 
oral mucosa a very attractive and selective site for systemic drug 
delivery [1,2] . There is a growing demand for novel dosage forms to 
cater the needs of pediatric and geriatric population. in order to assist 
or satisfy these patients, several fast disintegrating drug delivery 
systems have been developed and marketed. However such fast 
disintegrating solid preparations suffer from certain major drawbacks 
including fear of choking/swallowing, fragility and friability and 
requirement of specialized and expensive packaging [3]. Fast 
dissolving drug-delivery systems were first developed in the late 
1970s as an alternative to conventional dosage forms for pediatric 
and geriatric patients who experience difficulties in swallowing 
traditional oral solid-dosage form [4]. The fast dissolving drug 
delivery system are specially designed for the drugs which have 
extensive first pass metabolism and have low dose, for the 
enhancement of bioavailability [5].  
These systems consist of the solid dosage forms that disintegrate 
and dissolve quickly in the oral cavity without the administration of 
water. Research and development in the oral drug delivery segment 
has led to transition of dosage forms from simple conventional 
tablets or capsules to modified release tablets or capsules to oral 
disintegrating tablet (ODT) to wafer to the recent development of oral 
fast dissolving films (OFDFs). Amongst the plethora of avenues 
explored for the rapid drug releasing products, oral strip technology 
is gaining much attention [6].   
Vomiting, also known as emesis, throwing up, among other terms, is 
the involuntary, forceful expulsion of the contents of 
one's stomach through the mouth and sometimes the nose.  
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Vomiting can be caused by a wide variety of conditions, it may 
present as a specific response to ailments like gastritis or poisoning, 
or as a non-specific sequela of disorders ranging from brain 
tumors and elevated intracranial pressure to overexposure 
to ionizing radiation. The feeling that one is about to vomit is 
called nausea, which often proceeds, but does not always lead to, 
vomiting [7].  
Palonosetron HCl hydrochloride is a white to off-white crystalline 
powder. It is freely soluble in water, soluble in propylene glycol, and 
slightly soluble in ethanol and 2- propanol. It prevents acute and 
delayed nausea and vomiting associated with initial and repeat 
courses of moderately emetogenic cancer chemotherapy. 
Palonosetron HCl hydrochloride is being administered intravenously, 
as a single dose, 30 minutes before chemotherapy, or administered 
as a single oral capsule one hour before chemotherapy [8]. The 
present study is aim to formulate and characterize the fast dissolving 
oral films of Palonosetron HCl hydrochloride by solvent casting 
method for rapid onset of action in the management of migraine 
attack and also to improve the bioavailability of the drug.  
 
Materials and methods 
 
Materials 
 
Palonosetron HCl Hydrochloride was generous gift sample from 
MSN labs, Hyderabad, India. Hydroxy Propyl Methyl Cellulose 
(HPMC E3, E6 & E15) was gifted by Nectar life sciences, 
Hyderabad, Maltodextrin DE6 and Aspertame was gifted by MSN 
Labs, Xanthan gum was obtained from Matrix Labs, Hyderabad. 
Propylene glycol, Vanillin, Citric acid are laboratory grade, all other 
chemicals used were of analytical grade. 
 
Methods 
 
Determination of dose of Palonosetron HCl 
hydrochloride 
Amount of drug required per film = 0.5 mg of Palonosetron HCl  
Therefore, 4 films require 2mg of drug 
Area of the petridish (πr2) ==3.5*4.5*4.5=64cm2 
6 films of 4 cm2 each i.e. (2cm*2cm) can be obtained freely per 
petridish 
Area not required is the one remaining after cutting the films from the 
centre of petridish. This is obtained as 
Area considered= Sum of the areas of number of films taken= 4 
cm2*6=24 cm2 
Amount of drug in area considered= 3mg  
Area not considered= Total area of petridish-Area considered 
                               = 64-24= 40 cm2 
4 cm2 film contains 0.5 mg of drug therefore 40 cm2 contains 5mg of 
drug 
Amount of drug in area not considered= 5mg  
Therefore, 
Total drug dose = (Amount of drug in area considered) + (Amount of 
drug in area not considered) = 5mg + 3mg = 8mg  
Therefore, an approximate amount of 8mg drug was considered per 
petridish9  
 
Preparation of Palonosetron HCl hydrochloride films 
 
It was aimed to prepare to Fast Dissolving Oral Films of Palonosetron 
HCl Hydrochloride whose dose was 0.5mg per 4cm2 film. The 
procedure was carried out on a digital magnetic stirrer using a 
medium sized magnetic bead. Film forming polymers hypromellose 
and  maltodextrin were weighed accurately, added to a  small amount 
of water in a small beaker, covered with an aluminium foil and soaked 
foe 24 hours to ensure complete hydration. Xanthan gum was added 
the next day in small amounts and the solution was stirred on a 
magnetic stirrer at 75rpm for first half an hour and later 50rpm for 1.5 
hours. Then, propylene glycol was added and stirring continued for 
30min at 50rpm. Palonosetron HCl hydrochloride drug, aspartame, 
citric acid, vanillin and amaranth were dissolved in sufficient quantity 
of water and added to the polymer mixture. This film forming solution 
then stirred well to obtain a homogenous solution. Dry and clean 
petridish was selected and the solution was poured into it. Drying was 
carried out at 45°C in a hot air oven for 6 hours. The petridish was 
then removed and left aside to cool down to room temperature. The 
film was then peeled carefully using a surgical scalpel by making a 
small incision in the film on one side of the petridish. Small films of 
4cm2 were cut from one big film and packed primarily in aluminium 
foil and secondarily in self-sealing polythene to ensure least moisture 
penetration. The formulation was carried out using three different 
polymers, hypromellose E3, hypromellose E6 and hypromellose E15 
and the resulting films were evaluated. The composition of 
Palonosetron HCl hydrochloride fast dissolving oral films with 
different HPMC grades are shown in Table 1, 2 &3  
 
 
 
 
 
 
 
 
Table: 1 Formulation trials using HPMC E3 
Jyothi et al International Journal of Drug Delivery 8 (1) 23-36 [2016] 
 
 
  
PAGE | 25 | 
 
 
CODE & INDREDIANTS F1 F2 F3 F4 F5 F6 
PALONOSETRON HCL (mg) 8 8 8 8 8 8 
HPMC E3 (mg)    200 220 240 260 280 300 
MALTODEXTRIN 160 150 140 140 120 110 
PROPLYLENE GLYCOL 80 80 90 90 100 100 
XANTHAN GUM (mg) 10 10 8 8 6 6 
TWEEN 80 5 5 5 5 5 5 
ASPARTAME (mg) 20 20 20 20 20 20 
CITRIC ACID  (mg) 10 10 10 10 10 10 
WATER   (ml) Q.S Q.S Q.S Q.S Q.S Q.S 
VANILLA Q.S Q.S Q.S Q.S Q.S Q.S 
AMARANTH Q.S Q.S Q.S Q.S Q.S Q.S 
 
Table: 2 Formulation trials using HPMC E6 
CODE & INDREDIANTS F7 F8 F9 F10 F11 F12 F13 
PALONOSETRON HCL (mg) 8 8 8 8 8 8 8 
HPMC E6 (mg) 200 210 220 230 240 250 260 
MALTODEXTRIN 180 180 160 160 150 150 130 
PROPLYLENE GLYCOL 80 80 90 90 100 100 110 
XANTHAN GUM (mg) 10 10 8 8 8 6 6 
TWEEN 80 5 5 5 5 5 5 5 
ASPARTAME (mg) 20 20 20 20 20 20 20 
CITRIC ACID  (mg) 10 10 10 10 10 10 10 
WATER(ml) Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
VANILLA Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
AMARANTH Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
 
Table: 3 Formulation trials using HPMC E15 
CODE & INDREDIANTS F14 F15 F16 F17 F18 F19 F20 
PALONOSETRON HCL (mg) 8 8 8 8 8 8 8 
HPMC E15(mg) 200 210 220 230 240 250 260 
MALTODEXTRIN 180 180 160 160 150 150 130 
PROPLYLENE GLYCOL 80 80 90 90 100 100 110 
XANTHAN GUM (mg) 10 10 8 8 8 6 6 
TWEEN 80 5 5 5 5 5 5 5 
ASPARTAME (mg) 20 20 20 20 20 20 20 
CITRIC ACID (mg) 10 10 10 10 10 10 10 
WATER(ml) Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
VANILLA Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
AMARANTH Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
 
Evaluation of Palonosetron HCl hydrochloride fast 
dissolving oral films 
 
Physical characterization of FDOFs 
 
Physical characterization of FDOFs can be carried out by visual 
inspection for characteristics such as colour, thickness, brittleness, 
peeling ability, transparency, surface smoothness, tack property and 
film forming capacity. 
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Peeling ability: is measured as the easy or difficulty in separating the 
film from the release liner. 
Transparency: is checked by placing the film against an illuminated 
background and viewing carefully to find any opacity. 
Film forming capacity: is the ability of the film forming polymer to form 
an efficient film, thin enough and also with sufficient drug loading 
ability. Film forming capacity may be rated as poor, average, good 
and excellent based on the overall examination.  
The prepared films were subjected for in vitro evaluation tests like 
Thickness, Folding Endurance, Surface pH, Morphological 
properties, %Drug content and content uniformity, Tensile strength, 
Percent elongation, In vitro Disintegration time, In vitro Dissolution 
studies and in vivo studies on rabbits. 
 
Surface pH 
 
The film to be tested was placed in a Petri dish and was moistened 
with 0.5 ml of distilled water and kept for 30s. The pH was noted after 
bringing the electrode of the pH meter in contact with the surface of 
the formulation and allowing equilibration for 1 min. The average of 
three determinations for each formulation was done10.  
 
Weight variation and thickness  
 
For evaluation of film weight and thickness films were taken and 
weighed individually on a digital balance. The film thickness was 
measured using Digital Vernier caliper (Mitutoyo) at six different 
places and the average value was calculated.  
 
Folding endurance 
 
The folding endurance is expressed as the number of folds (number 
of times the film is folded at the same place) required to break the 
specimen or to develop visible cracks. This also gives an indication 
of brittleness of the film. A strip of 2.5 cm × 2.5 cm was subjected to 
folding endurance by folding the patch at the same place repeatedly 
several times until a visible crack was observed, and the values were 
reported.  
%Drug content  
Three films (4 cm2 of each) were transferred in to separate 
graduated flasks containing 100 ml of phosphate buffer pH 6.8 and 
continuously stirred for 2 hrs. The solutions were filtered, suitably 
diluted and analyzed at 227 nm and the drug content was calculated.  
 
Percent Elongation  
This mechanical property was evaluated using the Instron universal 
testing instrument (Model F. 4026, Instron Ltd., Japan) with a 5 kg 
load cell. The percentage increase in the length of a film (L2), when 
it is pulled under standard conditions of stress just before the point 
of break is known as percent elongation. The initial length of a film is 
L1, the increase in length is (L2-L1). It is measured in terms of 
percentage. Percent elongation and tensile strength was carried for 
only 4 best formulations. 
                                                     (L2- L1) 
Percent elongation =                                                           X 100 
       L1 X Cross sectional area 
 
Tensile strength 
Tensile strength is the maximum stress applied to a point at which 
the strip specimen breaks. Film strip of dimension 5 × 2 cm 2 and 
free from air bubbles or physical imperfections was held between 
two clamps positioned at a distance of 3 cm apart. A cardboard was 
attached on the surface of the clamp via a double sided tape to 
prevent the film from being cut by the grooves of the clamp. During 
measurement, the strips were pulled at the bottom clamp by adding 
weights in pan till the film breaks. The force was measured when the 
films broke.  It is calculated by the applied load at rupture divided by 
the cross‐sectional area of the strip as given in the equation below14:                                                                                 
                                                        
                                                        Load at failure 
Tensile strength         =               
                                                   Strip thickness X Stripwidth 
 
In vitro disintegration studies 
Disintegration test was performed to ensure the disintegration of the 
film in phosphate buffer pH 6.8. One film from each formulation was 
introduced into one tube of disintegration apparatus IP. A disc was 
added into the tube. The assembly was suspended in a beaker 
containing phosphate buffer pH 6.8 and the apparatus was operated 
until the film disintegrated.  
 
In vitro dissolution studies 
 
The phosphate buffer pH 6.8 was taken as the dissolution medium 
to determine the drug release. The dissolution profile of quick 
release films of Almotriptan malate was carried out in USP basket 
type apparatus containing 300 ml of the phosphate buffer pH 6.8. 
The film was placed in the basket, maintained at 37 ± 0.5°C and the 
agitation speed was 50 rpm. Aliquots (5 ml) of the dissolution 
medium were withdrawn at 1, 2, 4, 6, 8, 10 and 12 minutes time 
intervals and the same amount was replaced with the fresh medium. 
Samples were analyzed spectrophotometrically at 227 nm and the 
cumulative percentage of drug release was calculated.  
 
Drug excipient compatibility studies 
 
The drug excipient compatibility studies were carried out by Fourier 
Transmission Infrared Spectroscopy (FTIR) method and Differential 
Scanning Colorimetry (DSC) method. 
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Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra for pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The IR spectrum of the samples was 
prepared using KBr disks by means of hydraulic pellet press at 
pressure of seven to ten tons.  
 
Differential Scanning Calorimetry (DSC) 
 
Differential Scanning Calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. The DSC 
thermograms were recorded for pure drug, HPMC E15, Maltodextrin, 
Drug and HPMC mixture and optimized formulation. Accurately 
weighed samples were placed on aluminium plate, sealed with 
aluminium lids and heated at a constant rate of 5ºC /min, over a 
temperature range of 0 to 250ºC. 
 
Stability studies 
 
The stability study of the optimized fast-dissolving films was carried 
out under different conditions according to ICH guidelines. The film 
was packed in the aluminium foil and stored in a stability chamber 
for stability studies. Accelerated Stability studies were carried out at 
40 0C / 75 % RH for the best formulations for 6 months. The patches 
were characterized for the drug content and other parameters during 
the stability study period.  
 
Pharmacokinetic study 
 
Animal Preparation  
 
Twelve New Zealand white rabbits of either sex rabbits were 
(weighing 2-3 kg) selected for this study, all the animals were healthy 
during the period of the experiment. Animals were maintained at 
room temperature 250C, RH 45% and 12 h alternate light and dark 
cycle with 100 % fresh air exchange in animal rooms, uninterrupted 
power and water supply and rabbits were fed with standard diet and 
water ad libitum. The protocol of animal study was approved by the 
institutional animal ethics committee.  
 
In vivo Study design 
 
The rabbits were fasted overnight before administration of the 
formulations (ODF contain Palonosetron HCl Hydrochloride 0.5 mg) 
and Innovator (Palozen soft gelatine capsule 0.5mg). The rabbits 
were randomly divided into two groups each group contains six 
animals. The group A rabbits were anaesthetized with intravenous 
injection of pentobarbital in a dose of 25mg/kg then positioned on 
table with the lower jaw supported in a horizontal position and the 
ODF was carefully placed on the rabbit tongue. The innovator was 
administered orally to group B with equivalent to animal body weight. 
Blood samples for pharmacokinetic analysis were obtained at 
different time intervals 0, 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 
4.00, 5.00, 6.00, 8.00, 12.00, 16.00 & 24.00h after doing. Blood 
samples were collected in heparinised tubes and were centrifuged 
for 10min at 3,000 rpm at room temperature. 
 
Preparation of Plasma Samples for HPLC Analysis 
 
Rabbit plasma (0.5 ml) samples were prepared for chromatography 
by precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was re suspended with 
1 ml of acetonitrile by vortexing for 1 min. After centrifugation (5000 
– 6000 rpm for 10 min), the acetonitrile was added to the ethanol and 
the organic mixture was taken to near dryness by a steam of nitrogen 
at room temperature. Samples were reconstituted in 200 1 of 70 % 
of acetonitrile and 30% water was injected for HPLC analysis. 
For HPLC C18 column (ODS-UG-5, 250 ×4.6 mm, 5μ) and the 
mobile phase consisting of phosphate buffer (0.025M sodium 
dihydrogen phosphate pH adjusted to 6.9 with triethylamine) and 
Acetonitrile (65:35) at a flow rate of 1 ml/min with UV detection at 
240 nm. The retention time of Palonosetron HCl hydrochloride was 
4.722 min. internal standard zolmitripton was used. The retention 
time was 2.290min 17  
 
Pharmacokinetic Analysis  
 
The pharmacokinetic parameters, peak plasma concentrations 
(Cmax) and time to reach peak concentration (tmax) were directly 
obtained from concentration time data. In the present study, AUC0-t 
refers to the AUC from 0 to 24 hrs, which was determined by linear 
trapezoidal rule and AUC0- refers to the AUC from time at zero 
hours to infinity.  
The AUC0- was calculated using the formula AUC0-t + [Clast/K] 
where C last is the concentration in g/ml at the last time point and 
K is the elimination rate constant. 
Various pharmacokinetic parameters like area under the curve 
[AUC], elimination half life (t½). Volume of distribution (Vd), total 
clearance (ClT) and mean residence time for each subject using a 
non compartmental pharmacokinetic programme. The 
pharmacokinetic parameters were performed by a non 
compartmental analysis using Win Nonlin 3.3® pharmacokinetic 
software (Pharsight Mountain View, CA USA). All values are 
expressed as the mean ±SD. Statistical analysis was performed with 
Graph Pad InStat software (version 3.00, Graph Pad Software, San 
Diego, CA, USA) using one-way analysis of variance (ANOVA) 
followed by Tukey–Kramer multiple comparison test. Difference with 
p<0.05 was considered statistically significant. 
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Results and discussion 
Preparation of Palonosetron HCl oral films 
 
It was aimed to prepare fast dissolving oral films of Palonosetron HCl 
with the dose of 0.5mg per 4 cm2 film. Total 20 formulations were 
prepared each using three different polymers, HPMC E3, HPMC E6 
and HPMC E15. 
 
 
 
Figure 1: Palonosetron HCl Hydrochloride Films  
Physical Characterization of films 
 
Physical characterization of FDOFs was carried out by visual 
inspection and the following results were observed. 
The films were evenly colored and no migration of colour was 
observed. The increased thickness of film is attributed to the 
increase in the amount of HPMC. F1, F2, F3, F4, F5, F6, F8, F9, F10 
and F14 were found to brittle in nature due to insufficient amount of 
plasticizer added to the formulation. F5 and F6 are difficult to peel 
whereas others separated easily. 
F3, F4, F7, F12, F20 were found to be thick. F13& F19 were found 
to be excellent in film forming property, non-tacky, thin, flexible and 
easy to peel. Other formulations were found to be good film forming 
property. The films obtained from all the formulations had smooth 
surface on either side. Formulations prepared using HPMC E3 was 
not evaluated for physical parameters and other tests as they fail to 
satisfy the preliminary characteristics of films due to their poor film 
forming ability (Table 4). 
Evaluation of fast dissolving oral films of 
Palonosetron HCl Hydrochloride 
 
Thickness & Weight variation 
 
Thickness of all mouth dissolving films was measured with Digital 
Vernier Caliper (Mitutoyo) and found to be in the range of 74±2 to 
90±1 µm (Table 5). The optimized film has thickness of 82±1. A 
result of thickness measurement showed that as the concentration 
of polymer increases, thickness of mouth dissolving film also 
increases. The weight variation of the formulations was in the range 
of 22.53 to 32.43 mm, which was acceptable.  
 
Folding endurance 
 
Folding endurance gives an indication of brittleness of the film. It was 
shown that as the concentration of polymer and plasticizer 
increases, folding Endurance of mouth dissolving film increases. The 
folding endurance value of the prepared films ranged from 54+4 to 
115+2 (Table 5). The optimized film (F13) has folding endurance 
value of 115+2, which was desirable. 
 
Surface pH 
 
Surface pH of all mouth dissolving films prepared by using different 
polymers was found to be in the range of 6.5 to 6.9 pH (Table 5), 
which was close to the neutral pH, which indicated that films may 
have less potential to irritate the sublingual mucosa, and hence, 
more acceptable by the patients. 
 
%Drug content  
 
All the fast dissolving oral films were found to contain an almost 
uniform quantity of the drug, as per content uniformity studies 
indicating reproducibility of the technique. Drug content in the films 
was evaluated and the values were found to be between 95. 8 to 
98.22. % (Table 5) for three different cuts from each film. As per the 
USP requirements, the films found to meet the criteria for content 
uniformity. No significant difference in the drug content among the 
films indicated good content uniformity. 
 
In vitro disintegration studies 
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The disintegrating time of all the formulations was shown in Table 5.  
The disintegration time of optimized formulation (F13) was found to 
be 10 sec, which was very less and desirable for quick onset of 
action (Table 5 & Figure 2 & 3). 
Table 4: Preliminary Characterisation of FDOF’S 
Code and 
properties 
Film property Track property Ease of handling 
F1 Poor Non-tacky Thick & brittle 
F2 Poor Non-tacky Thick & brittle 
F3 Average Non-tacky Slightly thick & brittle 
F4 Average Non-tacky Slightly thick & brittle 
F5 Average Non-tacky Thin, brittle, difficult to peel 
F6 Average Tacky Thin, brittle, difficult to peel 
F7 Good Tacky Thick, easy to peel 
F8 Poor Non-tacky Brittle 
F9 Poor Non-tacky Brittle, slightly Opaque 
F10 Average Non-tacky Brittle, Opaque 
F11 Average Non-tacky Opaque, easy to peel 
F12 Average Tacky Thick, easy to peel 
F13 Excellent Non-Tacky Soft, Thin, easy to peel 
F14 Poor Non-tacky Brittle 
F15 Good Non-tacky Opaque, easy to peel 
F16 Good Non-tacky easy to peel 
F17 Good Non-tacky Slightly Opaque 
F18 Good Tacky Soft, easy to peel 
F19 Excellent Non-tacky Thin, easy to peel 
F20 Good Non-tacky Soft, Thick, easy to peel 
 
Table 5: Physical evaluation of fast dissolving oral films of Palonosetron HCl Hydrochloride 
Code  Thickness 
(µm) 
Weight Variation 
(mg) 
Folding 
Endurance 
(count) 
Surface pH % Drug Content  In vitro 
disintegratio
n time (sec) 
F6 74±2 27.1+0.12 56+1 6.55+0.03 95.8+0.23 25+2 
F7 76±1 29.1+0.17 62+1 6.68+0.04 95.58+1.2 26+2 
F8 81±3 32.43+0.95 54+2 6.54+0.11 92.44+0.6 22+2 
F9 80±2 28.56+0.20 54+4 6.82+0.01 92.3+0.1 27+2 
F10 83±2 28.36+0.20 62+1 6.76+0.01 83.4+0.6 25+2 
F11 88±1 27.1+0.12 67+3 6.90+0.02 95.5+0.2 23+2 
F12 86±2 28.14+0.21 66+4 6.62+0.1 93.68+0.15 15+2 
F13 82±1 26.66+3.21 115+2 6.75+0.05 98.22+0.22 10+2 
F14 84±0 32.53+0.95 83+4 6.77+0.05 95.32+0.3 18+2 
F15 90±1 27.1+0.12 101+5 6.93+0.02 92.4+0.6 13+2 
F16 85±0 24.3+3.05 96+2 6.77+0.02 86.7+2.2 25+2 
F17 82±2 22.53+0.95 110+3 6.67+0.01 90.5+1.8 17+2 
F18 85±1 28.56+0.20 83+4 6.77+0.05 97.32+0.3 15+2 
F19 82±1 27.1+0.12 108+2 6.81+0.01 96.7+0.1 13+2 
F20 81±2 24.26+0.26 99+1 6.78+0.01 97.6+1.6 14+2 
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Figure 2: In vitro Disintegration Time of HPMC E6 formulations 
 
 
Figure 3: In vitro Disintegration Time of HPMC E15 formulations 
 
 
Tensile strength and Percent Elongation 
 
The tensile testing gives an indication of the strength and elasticity 
of the film, reflected by the parameters, tensile strength and 
elongation at break. Tensile strength and percent elongation of all 
prepared formulation is shown in Table 6, found to be within the 
limits. Results revealed that optimized formulation (F13) showed 
better tensile strength (10.4 g/cm2) and moderate % elongation 
(9.7).  
 
 
 
Table 6: Tensile Strength and Percentage Elongation 
Formulation Code Tensile Strength (g/cm2) (%) Elongation  
F13 10.4 9.7 
F15 9.8 9.2 
F19 9.4 8.8 
F20 9.7 8.3 
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In vitro dissolution studies 
 
In-vitro drug dissolution study of formulation 
batches F6 to F13 
 
The cumulative % drug release for the formulations F7 to F20 are 
tabulated in Table 7, 8 & Figure 4 and 5. The optimized formulation 
(F13) shows highest percent of drug release 99.52 by the end of 
10min. The cumulative % drug release studies of optimized 
formulation F13 was compared with the marketed PALOGEN 
(0.5mg) and the drug release of F13 and innovator was found to be 
99.52 and 80.12  respectively after 10min. 
 
       
 
Table 7: Cumulative Percentage Drug Release for HPMC E6 
Time 
(min) 
Formulation Code 
 F7 F8 F9 F10 F11 F12 F13 
0 0 0 0 0 0 0 0 
1 37.45+1.5 40.04+1.4 32.2+3.01 35.7+1.11 42.5+2.045 45.2+2.55 48+1.52 
2 52.11+1.12 56.48+2.55 50.2+1.25 54.3+2.21 58.3+2.21 60.1+3.01 69.6+1.82 
4 67.47+1.22 72.2+30 66.85+2.74 64.5+2.09 74.2+2.66 76.2+2.54 90+1.05 
6 78.2+2.03 80.1+20 76.2+2.13 74.5+1.88 94.1+59 93.2+1.33 96.4+1.22 
8 82.3+2.1 89.6+26 86.2+5.1 83.2+2.88 98.1+2.69 96.2+2.31 99.4+2.69 
10 95.05+1.86 94.8+1.88 92+1.75 93+2.11 92.1+2.12 93+3.22 99.52+1.2 
 
 
 
 
 
 
 
 
Figure 4: Cumulative Percentage Drug Release for HPMC E6 
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Table 8: Cumulative Percentage Drug Release for HPMC E15 
Time 
(min) 
Formulation Code 
 F14 F15 F16 F17 F18 F19 F20 
0 0 0 0 0 0 0 0 
1 22.45+1.5 29.7+1.4 41.5+3.01 42.8+1.11 36.6+2.045 32.35+2.55 22.12+1.21 
2 37.25+1.12 55.3+2.55 50.5+1.25 63.5+1.68 40.23+2.21 40.81+1.62 38.52+1.4 
4 45.31+2.74 68.5+2.72 74.3+2.09 78.9+1.25 52.77+2.66 53.55+2.27 55.87+1.7 
6 51.36+2.68 75.7+3.05 83.4+3.55 85+2.36 62.47+1.88 68.8+3.21 70.55+1.5 
8 74.11+2.03 80.2+2.65 86.9+2.88 81.9+2.55 71.1+0.96 82.04+1.8 85.5+2.04 
10 86.54+1.86 95.6+1.88 91.7+1.75 93.5+2.71 88.9+1.48 96.35+1.18 96.6+3.11 
 
Figure 5: Cumulative Percentage Drug Release for HPMC E15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Comparison of Cumulative drug release of F13 with innovator product PALOZEN-0.5 mg soft gelatin capsules. 
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Drug excipient interactions studies by FTIR   
 
 
Figure 7: FTIR Spectroscopy of Palonosetron HCl Hydrochloride Pure Drug 
 
 
 
Figure 8: FTIR Spectroscopy of Palonosetron HCl Hydrochloride + Maltodextrin+ Xanthan gum + HPMC E6 
 
 
   Figure 9: FTIR Spectroscopy of Palonosetron HCl Hydrochloride optimized formulation F13 
 
  
3983.454  0.000
3774.278  4.852
3579.445  0.0003227.783  0.0003165.828  22.716
2898.375  4.841
2704.823  0.000
2155.677  124.839
1728.693  234.574
1606.762  302.9571389.263  36.038
1253.600  180.286
1027.535  -0.112
798.183  65.744736.166  0.000
Xanthum gum(4)
 3500  3000  2500  2000  1500  1000   500
    80
    70
    60
Wavenumber
%
T
r
a
n
s
m
it
t
a
n
c
e
Jyothi et al International Journal of Drug Delivery 8 (1) 23-36 [2016] 
 
 
  
PAGE | 34 | 
 
 
Interpretation of FTIR data 
 
The FTIR spectra of pure Palonosetron HCl Hydrochloride displayed 
band at 2874 cm-1 due to C-H stretch, at 1710 cm-1  due to C=O 
stretching, at 1659 cm-1  due to heterocyclic C=C stretching. The 
spectra also showed bands at 1188 cm-1 due to C-N stretching.   The 
FTIR spectrum of film containing Palonosetron HCl Hydrochloride 
exhibited characteristic bands consistent with the molecular 
structure of Palonosetron HCl Hydrochloride  such as bands at 2843 
cm-1due to C-H stretch, at 1728 cm-1 due to C=O stretching, at 1643 
cm-1 due to heterocyclic C=C stretching, at 1188 cm-1 due to C-N 
stretching. Thus, the presence of characteristic absorption bands of 
Palonosetron HCl Hydrochloride and the film containing 
Palonosetron HCl Hydrochloride suggest that there is no interaction 
takes place between the drug and excipients used in the formulation. 
 
 
   Figure 10: DSC thermogram of Palonosetron HCl pure drug (A) and optimized formulatin F13 (B) 
 
 
Interpretation of DSC data 
 
DSC Thermo gram revealed that there is no considerable change 
observed in melting endotherm of pure drug (290) and drug in 
optimized formulation (F13) (286). It indicates that there is no 
interaction takes place between drug and other excipients used in 
the formulation. 
 
Stability Studies  
 
Optimized formulation (F13) was selected for stability studies on the 
basis of fast drug release. Stability studies were conducted for 6 
months according to ICH guidelines. From these results it was 
concluded that, optimized formulation is stable and retained their 
original properties with minor differences which depicted in the table 
9. 
Table 9: Physico-chemical characteristics of optimized formulation (F19) stored at 40 ±2ºC /75 ±5%RH 
Retest Time For 
Optimized 
formulation 
Disintegrating Time 
(sec) 
% Drug Content  In-vitro drug 
release profile 
(%) 
Transparency 
0 days 10+ 2 98.22 99.52 Transparent 
30 days 11+ 1 97.45 98.14 Transparent 
60 days 11+ 9 97.06 97.68 Transparent 
90 days  12+ 2 96.54 96.23 Transparent 
180 days  12+ 6 96.54 96.23 Transparent 
 
 
 
 
 
Pharmacokinetic study 
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Figure 11: Plasma concentrations at different time intervals of Palonosetron HCl Hydrochloride Optimized formulation (F13) and 
Innovator 
 
Table 10: Comparison of pharmacokinetic parameters of Palonosetron HCl Hydrochloride between the optimized formulation film and 
innovator (Palozen soft gelatine capsule 0.5mg) in Rabbits (mean ± SD, n = 6). 
 
Parameters Optimized formulation Film Innovator 
Cmax(ng/ml) 0.318±0.1 0.213±0.1 
AUC0-t(ng hr/ml) 1.06±0.44 0.95±0.26 
AUC0–∞(ng hr/ml) 1.14±0.14 1.04±0.12 
Tmax(h) 0.50±0.5 1.5±0.1 
t1/2(h) 1.253 ± 0.519 2.664 ± 0.01 
Kel (hr-1) 1.336 ± 0.11 1.196  
 
 
Pharmacokinetic parameters comparison for 
Palonosetron HCl Hydrochloride optimized film and 
innovator product 
 
The mean Palonosetron HCl Hydrochloride plasma concentrations - 
time profiles for the prepared Palonosetron HCl Hydrochloride film 
and innovator are shown in figure 11. The bioavailability parameters 
for the both test film and reference standard are summarized in 
Table 10. Mean time to reach peak drug concentration (Tmax) was 
0.50±0.5h and 1.5±0.1h for the optimized and commercial 
formulations, respectively, while mean maximum drug concentration 
(Cmax) was 0.318±0.1ng/ml and 0.213±0.1ng/ml, respectively. The 
statistical comparison of AUC0-∞ and AUC0–t indicated no 
significant difference between the two treatments, and there was a 
significant difference for the Cmax and Tmax was observed in this 
study. As the prepared films were exhibited immediate release and 
capsules were shown prolonged release, as prepared formulation 
shown immediate release so it was shown significantly increased 
maximum concentration when compared with marketed product. 
 
Summary and conclusion 
 
Fast dissolving Oral film of Palonosetron HCl was formulated by 
using solvent casting method with different concentrations of HPMC-
E3, E6 and E15. Formulations with HPMC E3 were not evaluated for 
other physical parameters due to their poor film forming ability, tack 
property and ease of handling or peeling. Dissolution studies were 
performed for FDOFs excluding batches that showed poor film 
forming property. Among the prepared formulations F13 showed 
minimum disintegration time 10 sec.  Formulation F13 was shown 
fast release of the drug 99.52% within 10min when compared to the 
-0.05
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0 10 20 30
Optimized
fromulation(F13)
Innovator Product
Time (h)
P
la
sm
a 
d
ru
g 
C
on
ce
n
tr
at
io
n
s(
n
g/
m
l)
Jyothi et al International Journal of Drug Delivery 8 (1) 23-36 [2016] 
 
 
  
PAGE | 36 | 
 
 
other formulations. Based on the physicochemical properties like 
tensile strength, folding endurance, thickness, disintegration results 
and dissolution studies, it was concluded that F13 finalized as 
optimized formulation. 
DSC and FTIR data revealed that no interactions takes place 
between the drug and polymers used in the optimized formulation. 
The in vitro dissolution profiles of marketed product (PALOZEN) and 
optimized formulation was compared and found to be the drug 
released was 72% within 7min from the marketed product, whereas 
from optimized formulation (F13) the drug release was 96.4% within 
7min. Therefore it can be a good alternative to conventional 
Palonosetron HCl capsules. 
The in vitro dissolution profiles of marketed product (PALOGEN 
0.5mb) and optimized formulation (F13) was compared and found to 
be 80.12% within 10min from the marketed product, whereas from 
optimized formulation (F13) the drug release was 99.52% 
respectively within 10min. Therefore it can be a good alternative to 
conventional Palonosetron for immediate action. 
In vivo study exhibited both optimized formulation and innovator 
shown comparable drug -plasma level- time profiles in vivo 
evaluation of the films confirmed their potential as an innovative 
dosage form to achieve immediate action and improvement in the 
bioavailability of the drug. Therefore, the oral dissolving film is 
considered to be potentially useful for the treatment of emesis where 
quick on set of action, improved patient compliance and comfort is 
expected. FDOFs are suitable dosage forms in disease conditions 
like chemotherapy induced nausea and vomiting (CINV) as these 
dosage forms are patient compliant as well as show rapid onset of 
action as they are quick dissolving dosage forms. It can be especially 
useful for geriatric, bedridden, and non-cooperative patients due to 
its ease of administration.  
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